Thursday, November 03, 2022 9:24:17 AM
doubt someone will buy them out for the current development.
Now if they start to see 'success' with their other product lines, I could see a buy out happening, but they are still years away from getting that kind of 'confirmation' that the developments 'really' do work.
My plan was to hold onto some shares, take gains on the rest, and only hold them IF i could get decent covered call 'returns' on a frequent basis. Otherwise, sell them all and try something else while I waited and watched.
Now if they start to see 'success' with their other product lines, I could see a buy out happening, but they are still years away from getting that kind of 'confirmation' that the developments 'really' do work.
My plan was to hold onto some shares, take gains on the rest, and only hold them IF i could get decent covered call 'returns' on a frequent basis. Otherwise, sell them all and try something else while I waited and watched.
Recent ATNM News
- Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs • PR Newswire (US) • 05/29/2026 09:31:00 PM
- Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice • PR Newswire (US) • 05/29/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 09:10:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 09:00:35 PM
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting • PR Newswire (US) • 04/06/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:32 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/26/2026 09:00:06 PM
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting • PR Newswire (US) • 02/17/2026 12:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 10:00:30 PM
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer • PR Newswire (US) • 12/12/2025 01:45:00 PM
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium • PR Newswire (US) • 12/01/2025 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 10:00:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:50:40 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2025 10:03:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/05/2025 10:02:26 PM
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications • PR Newswire (US) • 11/04/2025 12:30:00 PM
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference • PR Newswire (US) • 11/03/2025 01:30:00 PM
- Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecu • PR Newswire (US) • 10/27/2025 11:00:00 AM
- Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat • PR Newswire (US) • 10/24/2025 12:30:00 PM
- Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 10/13/2025 04:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2025 09:00:25 PM
